MARKET

TCRX

TCRX

Tscan Therapeutics, Inc.
NASDAQ
0.7788
+0.0068
+0.88%
After Hours: 0.7800 +0.0012 +0.15% 19:58 08/14 EDT
OPEN
0.7680
PREV CLOSE
0.7720
HIGH
0.7889
LOW
0.7410
VOLUME
278.42K
TURNOVER
--
52 WEEK HIGH
2.570
52 WEEK LOW
0.7160
MARKET CAP
52.79M
P/E (TTM)
-0.8594
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX), Humacyte (HUMA) and TScan Therapeutics (TCRX)
TipRanks · 2d ago
TScan Advances TSC-101; Phase 3 Topline Data Expected In 2028
NASDAQ · 3d ago
TScan Therapeutics Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 3d ago
HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $7 Price Target
Benzinga · 3d ago
Analysts Are Bullish on These Healthcare Stocks: TScan Therapeutics (TCRX), Eli Lilly & Co (LLY)
TipRanks · 3d ago
Analysts Offer Insights on Healthcare Companies: Immix Biopharma (IMMX), TScan Therapeutics (TCRX) and enGene Holdings (ENGN)
TipRanks · 3d ago
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
NASDAQ · 3d ago
*TScan Therapeutics 2Q Research and Development Expenses $23.4M >TCRX
Dow Jones · 3d ago
More
About TCRX
TScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.

Webull offers Tscan Therapeutics Inc stock information, including NASDAQ: TCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TCRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TCRX stock methods without spending real money on the virtual paper trading platform.